HomeVeracyte, Inc.

Veracyte, Inc.

Veracyte and MAVIDx Agreement in Place

Veracyte and MAVIDx agreement is intended to enable diagnostic testing and population screening for COVID-19 at an unprecedented scale – up to 40,000 samples per day performed on the easy-to-use nCounter instrument – through technology that attaches molecular barcodes to individual RNA molecules of the virus. 

Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer

3/19/19: The findings on this rare, but aggressive form of thyroid cancer will be presented in a guided poster presentation during the conference, which is taking place March 23-26 in New Orleans, La.

Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis

10/8/18: The data showed Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

Veracyte Announces Presentation of New Clinical Utility Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis

Veracyte, Inc. today announced that data from a prospective clinical utility study show that use of the company’s Percepta Bronchial Genomic Classifier reduces invasive procedures by greater than 50 percent in lung cancer screening and diagnosis.